J Neurocrit Care.  2022 Dec;15(2):146-147. 10.18700/jnc.220080.

Axitinib-induced posterior reversible encephalopathy syndrome in a patient with renal cell carcinoma

• Sung E
• Kim H
• Sung W
• Park J

• KMID: 2538774
• DOI: http://doi.org/10.18700/jnc.220080

Figure

• 

  Fig. 1. Brain magnetic resonance imaging scans performed 2 hours after the seizure. (A) Diffusion-weighted images did not show any remarkable findings. (B) Fluid-attenuated inversion recovery images showed extensive multifocal high signal change at bilateral cerebral cortex, subcortical white matter, bilateral medial thalamus, pons and cerebellum.

Reference

1. Moghaddam AS, Ramaiah G, Jumaa M, Zaidi S. Posterior reversible encephalopathy syndrome (PRES) secondary to use of axitinib in renal cell cancer (P4. 012). Neurology. 2018; 90(15 Suppl):P4.012.

2. Levy A, Benmoussa L, Ammari S, Albiges L, Escudier B. Reversible posterior leukoencephalopathy syndrome induced by axitinib. Clin Genitourin Cancer. 2014; 12:e33–4.

3. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011; 6:253–8.